Stock Track | Monopar Therapeutics Soars 8.74% Following Analyst's Buy Rating and $130 Price Target

Stock Track

2025/11/19

Monopar Therapeutics (MNPR) stock surged 8.74% during Tuesday's intraday trading session, following a bullish analyst report. The significant uptick in share price comes as investors react positively to the reaffirmed buy rating and ambitious price target.

JonesTrading analyst Soumit Roy maintained a Buy rating on Monopar Therapeutics, setting a price target of $130.00. While specific details were not provided in the brief report, the analyst's optimistic stance suggests confidence in the company's pipeline and financial position. The substantial gap between the current trading price and the analyst's target indicates a potential for significant upside, which likely contributed to the day's strong stock performance.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1182700154"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182700154\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182700154?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182700154","market":"hk","top_or_hot":-1,"title":"Stock Track | Monopar Therapeutics Soars 8.74% Following Analyst's Buy Rating and $130 Price Target","media":"Stock Track","content":"<p>Monopar Therapeutics (MNPR) stock surged 8.74% during Tuesday's intraday trading session, following a bullish analyst report. The significant uptick in share price comes as investors react positively to the reaffirmed buy rating and ambitious price target.</p>\n\n<p>JonesTrading analyst Soumit Roy maintained a Buy rating on Monopar Therapeutics, setting a price target of $130.00. While specific details were not provided in the brief report, the analyst's optimistic stance suggests confidence in the company's pipeline and financial position. The substantial gap between the current trading price and the analyst's target indicates a potential for significant upside, which likely contributed to the day's strong stock performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Monopar Therapeutics Soars 8.74% Following Analyst's Buy Rating and $130 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Monopar Therapeutics Soars 8.74% Following Analyst's Buy Rating and $130 Price Target\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-11-19 03:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Monopar Therapeutics (MNPR) stock surged 8.74% during Tuesday's intraday trading session, following a bullish analyst report. The significant uptick in share price comes as investors react positively to the reaffirmed buy rating and ambitious price target.</p>\n\n<p>JonesTrading analyst Soumit Roy maintained a Buy rating on Monopar Therapeutics, setting a price target of $130.00. While specific details were not provided in the brief report, the analyst's optimistic stance suggests confidence in the company's pipeline and financial position. The substantial gap between the current trading price and the analyst's target indicates a potential for significant upside, which likely contributed to the day's strong stock performance.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNPR","symbol_name":"Monopar Therapeutics","start_time":0,"source_url":"","article_id":"1182700154","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182700154","pubTimestamp":1763492536,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Monopar Therapeutics (MNPR) stock surged 8.74% during Tuesday's intraday trading session, following a bullish analyst report. The significant uptick in share price comes as investors react positively...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNPR":"Monopar Therapeutics"},"translate_title":"股票追踪|Monopar Therapeutics在分析师给予买入评级和130美元目标价后飙升8.74%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":1},"content_text":"Monopar Therapeutics (MNPR) stock surged 8.74% during Tuesday's intraday trading session, following a bullish analyst report. The significant uptick in share price comes as investors react positively to the reaffirmed buy rating and ambitious price target.\nJonesTrading analyst Soumit Roy maintained a Buy rating on Monopar Therapeutics, setting a price target of $130.00. While specific details were not provided in the brief report, the analyst's optimistic stance suggests confidence in the company's pipeline and financial position. The substantial gap between the current trading price and the analyst's target indicates a potential for significant upside, which likely contributed to the day's strong stock performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}